Ethos Discovery de novo study
Cannabidiol (CBD) is the most promising phytocannabinoid, owing to its non-psychotropic effects, low toxicity, and high tolerability. Before pursuing trials to evaluate the efficacy of CBD in a given condition, its chronic pharmacokinetics (how the drug is processed in the body) must be performed. This study will evaluate the chronic pharmacokinetics of CBD, which will then allow for the determination of appropriate dosing in future therapeutic trials. Following this, a second study will be performed to investigate CBD’s efficacy at treating idiopathic epilepsy in dogs. It has previously been shown that cannabinoid receptors are widely distributed throughout the central nervous system and dogs with epilepsy have been demonstrated to have elevated endocannabinoid levels in their spinal fluid. This suggests that the endocannabinoid system possibly serves as a counter-mechanism in order to regulate seizures and indicates a possible therapeutic target to treat epilepsy.
- Dogs that are older than 6 months and weigh more than 5kg
- Dogs with a history of idiopathic epilepsy
- To be decided
Enroll or request more information below